– Preclinical studies published in Nature Biotechnology identify key biomarkers of SYNB1618 activity in healthy animals and disease models – – Clinical data expected in 2018 from healthy volunteer cohorts of ongoing Phase 1/ 2a study of SYNB1618; data from patients with phenylketonuria (PKU) in
- Data from Phase 1/2 studies of SYNB1618 and SYNB1020 expected by end of 2018 – – On track to advance first immuno-oncology program into IND-enabling studies in fourth quarter of 2018 – CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 8, 2018-- Synlogic, Inc.
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 7, 2018-- Synlogic (Nasdaq:SYBX) announced today that Aoife Brennan , M.B., B.Ch., Synlogic’s interim president and chief executive officer, and chief medical officer, will present a corporate update at the 2018 Wedbush PacGrow Healthcare Conference at
- Data highlight broad capabilities of Synlogic’s Synthetic Biotic platform to generate candidates for the potential treatment of cancer – - First program advancing into IND-enabling studies in 2H2018 – CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 25, 2018-- Synlogic , Inc. ( Nasdaq: SYBX ), a
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 25, 2018-- Synlogic, Inc. ( Nasdaq: SYBX ), a clinical stage company applying synthetic biology to probiotics to develop novel, living medicines, today announced the company’s addition to the Russell 3000® Index, following the Russell US Indices’ annual
– SYNB1618 currently being evaluated in a Phase 1/2a clinical trial in healthy volunteers and patients with Phenylketonuria (PKU); interim data expected in 2H 2018 – – Data presented in plenary session at ASM Microbe 2018 demonstrate lowering of blood phenylalanine (Phe) levels in an animal model
– SYNB1020 currently being evaluated in a Phase 1b/2a clinical trial in patients with elevated ammonia due to cirrhosis; topline data expected by YE2018 – CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 4, 2018-- Synlogic , Inc. ( Nasdaq: SYBX ), a clinical-stage drug discovery and development company
– Treated first subject in clinical trials of two Synthetic Biotic TM medicines, SYNB1020 and SYNB1618; both studies expected to generate data in 2018 – CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 15, 2018-- Synlogic, Inc. ( Nasdaq: SYBX ), a clinical stage company applying synthetic biology to
– Jose Carlos Gutiérrez- Ramos resigns as Synlogic’s President and Chief Executive Officer and member of its board of directors – – Aoife Brennan , current Synlogic Chief Medical Officer, named Interim President and Chief Executive Officer – CAMBRIDGE, Mass.
– Phase 1/2a clinical study of SYNB1618 evaluating safety and tolerability as well as exploratory endpoints expected to report interim data in 2018 – CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 25, 2018-- Synlogic ( Nasdaq: SYBX ), a clinical-stage company applying synthetic biology to probiotic
